R M Meyer
Overview
Explore the profile of R M Meyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Balitsky A, Pond G, Davies G, Fraser G, Kouroukis T, Levine M, et al.
BMC Cancer
. 2024 Aug;
24(1):984.
PMID: 39123197
Purpose: Chimeric antigen receptor T-cell (CART) therapy has shown clinical efficacy in refractory and relapsed large B-cell lymphomas, but is associated with serious acute and long-term toxicities. To understand the...
2.
Hay A, Rae C, Fraser G, Meyer R, Abbott L, Bevan S, et al.
Curr Oncol
. 2016 Apr;
23(2):e81-5.
PMID: 27122988
No abstract available.
3.
Desportes J, Metcalfe N, Popp J, Meyer R, Gallo A, Cezilly F
Behav Processes
. 2014 Jun;
22(1-2):41-6.
PMID: 24896921
While foraging, many animals alternate between feeding and scanning. Spectral analysis of continuous series of scan durations S and inter-scan intervals I for American Goldfinches Carduelis tristis, feeding either on...
4.
Meyer R, Burgos-Robles A, Liu E, Correia S, Goosens K
Mol Psychiatry
. 2013 Oct;
19(12):1284-94.
PMID: 24126924
Hormones in the hypothalamus-pituitary-adrenal (HPA) axis mediate many of the bodily responses to stressors, yet there is no clear relationship between the levels of these hormones and stress-associated mental illnesses...
5.
Hay A, Klimm B, Chen B, Goergen H, Shepherd L, Fuchs M, et al.
Ann Oncol
. 2013 Oct;
24(12):3065-9.
PMID: 24121121
Background: Treatment options for patients with nonbulky stage IA-IIA Hodgkin lymphoma include combined modality therapy (CMT) using doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus involved-field radiation therapy (IFRT), and chemotherapy...
6.
Ramjeesingh R, Meyer R, Brouwers M, Chen B, Booth C
Curr Oncol
. 2013 Feb;
20(1):e21-33.
PMID: 23444033
Background: We evaluated clinical practice guideline (cpg) recommendations from Cancer Care Ontario's Program in Evidence-Based Care (pebc) for molecularly targeted systemic treatments (tts) and subsequent funding decisions from the Ontario...
7.
KAY A, Higgins J, Day A, Meyer R, Booth C
Ann Oncol
. 2011 Nov;
23(6):1646-51.
PMID: 22048151
Background: We previously reported metrics of systemic therapy randomized controlled trials (RCTs) in breast cancer, colorectal cancer (CRC), and non-small-cell lung cancer (NSCLC) published 1975-2004. To evaluate trends in the...
8.
Meyer R
Can Fam Physician
. 2011 Jan;
31:1231-7.
PMID: 21274078
The features of multiple myeloma are due to plasma cell proliferation and the production of a monoclonal antibody. Skeletal disease with hypercalcemia, bone marrow dysfunction, sepsis, and renal failure are...
9.
Cheung M, Maceachern J, Haynes A, Meyer R, Imrie K
Curr Oncol
. 2009 Oct;
16(5):32-47.
PMID: 19862360
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Initial studies of (131)I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or...
10.
Courneya K, Booth C, Gill S, OBrien P, Vardy J, Friedenreich C, et al.
Curr Oncol
. 2008 Dec;
15(6):279-85.
PMID: 19079628
Background: Observational studies indicate that physical activity (PA) is strongly associated with improved disease outcomes in colon cancer survivors, but a randomized controlled trial is needed to determine whether the...